人 pTau217 抗体对
01AB00060
Plasma p-tau217 is a biomarker associated with Alzheimer's disease (AD) pathology. Research has shown that plasma p-tau217 is a sensitive marker of the clinical manifestation and progression of AD, including amyloid accumulation, tau burden, brain atrophy, and physical degradation. It has been found to be a potential non-invasive biomarker of AD, with high diagnostic accuracy in differentiating AD from other neurodegenerative diseases. Plasma p-tau217 has also been associated with longitudinal increases in Aβ PET uptake and cognitive decline in Aβ-positive clinically unimpaired individuals. Additionally, higher baseline p-tau217 levels have been linked to greater future tau PET pathology burden and worse future memory performance. These findings suggest that plasma p-tau217 could serve as a minimally invasive diagnostic and prognostic biomarker for AD, with potential utility in clinical practice and trials.
| 规格 | 起售价 |
|---|---|
| 登录后可查看 | |
技术参数
- 靶点基因名
- MAPT
- 蛋白别名
- Microtubule-associated protein tau; pTau217
- UniProt
- P10636-8
- 物种
- Human
产品详情
- 靶点名称
- pTau217
- 蛋白名称
- Microtubule-associated protein tau
- 靶点基因名
- MAPT
- UniProt
- P10636-8
- 来源物种
- Homo sapiens (Human)
- 物种反应性
- Human
背景介绍
Plasma p-tau217 is a biomarker associated with Alzheimer's disease (AD) pathology. Research has shown that plasma p-tau217 is a sensitive marker of the clinical manifestation and progression of AD, including amyloid accumulation, tau burden, brain atrophy, and physical degradation. It has been found to be a potential non-invasive biomarker of AD, with high diagnostic accuracy in differentiating AD from other neurodegenerative diseases. Plasma p-tau217 has also been associated with longitudinal increases in Aβ PET uptake and cognitive decline in Aβ-positive clinically unimpaired individuals. Additionally, higher baseline p-tau217 levels have been linked to greater future tau PET pathology burden and worse future memory performance. These findings suggest that plasma p-tau217 could serve as a minimally invasive diagnostic and prognostic biomarker for AD, with potential utility in clinical practice and trials.